Thrombin-activatable fibrinolysis inhibitor influences disease severity in humans and mice with pneumococcal meningitis

Journal of Thrombosis and Haemostasis

Volumn 13, Issue 11, 2015, Pages 2076-2086

  Mook Kanamori, B B ^a   Valls Seron M ^a   Geldhoff, M ^a   Havik, S R ^a   van der Ende, A ^a   Baas, F ^a   van der Poll, T ^a   Meijers, J C M ^a   P Morgan, B ^b   Brouwer, M C ^a   van de Beek, D ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

Streptococcus pneumoniae; Blood coagulation; Complement system proteins; Pneumococcal meningitis; Thrombin activatable fibrinolysis inhibitor

Indexed keywords

CARBOXYPEPTIDASE B; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C3B; COMPLEMENT COMPONENT C5B; COMPLEMENT MEMBRANE ATTACK COMPLEX; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 2; THROMBIN; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; THROMBOMODULIN; TUMOR NECROSIS FACTOR ALPHA; CPB2 PROTEIN, HUMAN; CPB2 PROTEIN, MOUSE; CYTOKINE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIAL MENINGITIS; BLOOD SAMPLING; BRAIN HEMORRHAGE; BRAIN INFARCTION; CEREBROSPINAL FLUID ANALYSIS; COHORT ANALYSIS; COLONY FORMING UNIT; COMMUNITY ACQUIRED INFECTION; COMPLEMENT SYSTEM; CONTROLLED STUDY; CPB2 GENE; DISEASE SEVERITY; DISSEMINATED INTRAVASCULAR CLOTTING; DNA ISOLATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FEVER; FIBRINOLYSIS; GENE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPING TECHNIQUE; GLASGOW COMA SCALE; GLASGOW OUTCOME SCALE; HEADACHE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; IMMUNOCOMPROMISED PATIENT; MAJOR CLINICAL STUDY; MENTAL DISEASE; MORBIDITY; MORTALITY; MOUSE; NECK PAIN; NEISSERIA MENINGITIDIS; NONHUMAN; OTITIS; PNEUMOCOCCAL MENINGITIS; PNEUMONIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RESPIRATORY FAILURE; SEROTYPE; SHOCK; SINGLE NUCLEOTIDE POLYMORPHISM; SINUSITIS; STREPTOCOCCUS PNEUMONIAE; SYMPTOMATOLOGY; AGED; ANIMAL; BLOOD; BRAIN DAMAGE, CHRONIC; C57BL MOUSE; CEREBRAL HEMORRHAGE; CEREBROSPINAL FLUID; COMPLICATION; DEFICIENCY; EPIDEMIC MENINGITIS; GENETICS; MALE; MIDDLE AGED; PHYSIOLOGY; RESPIRATORY INSUFFICIENCY; SHOCK, SEPTIC; TREATMENT OUTCOME;

ADULT; AGED; ANIMALS; BRAIN DAMAGE, CHRONIC; CARBOXYPEPTIDASE B2; CEREBRAL HEMORRHAGE; COMMUNITY-ACQUIRED INFECTIONS; COMPLEMENT C3A; COMPLEMENT C3B; COMPLEMENT MEMBRANE ATTACK COMPLEX; CYTOKINES; FEMALE; FIBRINOLYSIS; HUMANS; MALE; MENINGITIS, MENINGOCOCCAL; MENINGITIS, PNEUMOCOCCAL; MICE; MICE, INBRED C57BL; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RESPIRATORY INSUFFICIENCY; SHOCK, SEPTIC; TREATMENT OUTCOME;

EID: 84947020122     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.13132     Document Type: Article

References (36)

1. van de Beek D, de Gans J, Spanjaard L, Weisfelt M, Reitsma JB, Vermeulen M. Clinical features and prognostic factors in adults with bacterial meningitis. N Engl J Med 2004; 351: 1849-59.
2. van de Beek D, Schmand B, de Gans J, Weisfelt M, Vaessen H, Dankert J, Vermeulen M. Cognitive impairment in adults with good recovery after bacterial meningitis. J Infect Dis 2002; 186: 1047-52.
3. Heckenberg SGB, Brouwer MC, van der Ende A, Hensen EF, van de Beek D. Hearing loss in adults surviving pneumococcal meningitis is associated with otitis and pneumococcal serotype. Clin Microbiol Infect 2012; 18: 849-55.
4. Mook-Kanamori BB, Geldhoff M, van der Poll T, van de Beek D. Pathogenesis and pathophysiology of pneumococcal meningitis. Clin Microbiol Rev 2011; 24: 557-91.
5. Schut ES, Lucas MJ, Brouwer MC, Vergouwen MDI, van der Ende A, van de Beek D. Cerebral infarction in adults with bacterial meningitis. Neurocrit Care 2011; 16: 421-7.
6. Mook-Kanamori BB, Fritz D, Brouwer MC, van der Ende A, van de Beek D. Intracerebral hemorrhages in adults with community associated bacterial meningitis in adults: should we reconsider anticoagulant therapy? PLoS ONE 2012; 7: e45271.
7. Brouwer MC, Read RC, van de Beek D. Host genetics and outcome in meningococcal disease: a systematic review and meta-analysis. Lancet Infect Dis 2010; 10: 262-74.
8. Marx PF, Verkleij CJN, Valls Serón M, Meijers JCM. Recent developments in thrombin-activatable fibrinolysis inhibitor research. Mini Rev Med Chem 2009; 9: 1165-73.
9. Kim PY, Kim PYG, Taylor FB, Nesheim ME. Thrombin-activatable fibrinolysis inhibitor is activated in vivo in a baboon model of Escherichia coli induced sepsis. J Thromb Thrombolysis 2012; 33: 412-15.
10. Campbell WD, Lazoura E, Okada N, Okada H. Inactivation of C3a and C5a octapeptides by carboxypeptidase R and carboxypeptidase N. Microbiol Immunol 2002; 46: 131-4.
11. Watanabe R, Wada H, Watanabe Y, Sakakura M, Nakasaki T, Mori Y, Nishikawa M, Gabazza EC, Nobori T, Shiku H. Activity and antigen levels of thrombin-activatable fibrinolysis inhibitor in plasma of patients with disseminated intravascular coagulation. Thromb Res 2001; 104: 1-6.
12. Fouassier M, Moreau D, Thiollière F, Frère C, Marquès-Verdier A, Souweine B. Evolution of thrombin formation and fibrinolysis markers, including thrombin-activatable fibrinolysis inhibitor, during severe meningococcemia. Pathophysiol Haemost Thromb 2005; 34: 284-7.
13. Zeerleder S, Schroeder V, Hack CE, Kohler HP, Wuillemin WA. TAFI and PAI-1 levels in human sepsis. Thromb Res 2006; 118: 205-12.
14. Emonts M, de Bruijne ELE, Guimarães AHC, Declerck PJ, Leebeek FWG, de Maat MPM, Rijken DC, Hazelzet JA, Gils A. Thrombin-activatable fibrinolysis inhibitor is associated with severity and outcome of severe meningococcal infection in children. J Thromb Haemost 2008; 6: 268-76.
15. Chen C-C, Lee K-D, Gau J-P, Yu Y-B, You J-Y, Lee S-C, Hsu H-C, Chau W-K, Ho C-H. Plasma antigen levels of thrombin-activatable fibrinolysis inhibitor did not differ in patients with or without disseminated intravascular coagulation. Ann Hematol 2005; 84: 675-80.
16. Renckens R, Roelofs JJTH, ter Horst SAJ, van't Veer C, Havik SR, Florquin S, Wagenaar GTM, Meijers JCM, van der Poll T. Absence of thrombin-activatable fibrinolysis inhibitor protects against sepsis-induced liver injury in mice. J Immunol 2005; 175: 6764-71.
17. Woehrl B, Brouwer MC, Murr C, Heckenberg SGB, Baas F, Pfister HW, Zwinderman AH, Morgan BP, Barnum SR, van der Ende A, Koedel U, van de Beek D. Complement component 5 contributes to poor disease outcome in humans and mice with pneumococcal meningitis. J Clin Invest 2011; 121: 3943-53.
18. Jennett B, Teasdale G, Braakman R, Minderhoud J, Knill-Jones R. Predicting outcome in individual patients after severe head injury. Lancet 1976; 1: 1031-4.
19. Brouwer MC, Meijers JCM, Baas F, van der Ende A, Pfister HW, Giese A, van de Beek D, Koedel U. Plasminogen activator inhibitor-1 influences cerebrovascular complications and death in pneumococcal meningitis. Acta Neuropathol 2014; 127: 553-64.
20. Brouwer MC, van der Ende A, Baas F, van de Beek D. Genetic variation in GLCCI1 and dexamethasone in bacterial meningitis. J Infect 2012; 65: 465-7.
21. Geldhoff M, Mook-Kanamori BB, Brouwer MC, Valls Serón M, Baas F, van der Ende A, van de Beek D. Genetic variation in inflammasome genes is associated with outcome in bacterial meningitis. Immunogenetics 2013; 65: 9-16.
22. Mosnier LO, von dem Borne PA, Meijers JC, Bouma BN. Plasma TAFI levels influence the clot lysis time in healthy individuals in the presence of an intact intrinsic pathway of coagulation. Thromb Haemost 1998; 80: 829-35.
23. Mook-Kanamori B, Geldhoff M, Troost D, van der Poll T, van de Beek D. Characterization of a pneumococcal meningitis mouse model. BMC Infect Dis 2012; 12: 71.
24. te Velde EA, Wagenaar GTM, Reijerkerk A, Roose-Girma M, Borel Rinkes IHM, Voest EE, Bouma BN, Gebbink MFBG, Meijers JCM. Impaired healing of cutaneous wounds and colonic anastomoses in mice lacking thrombin-activatable fibrinolysis inhibitor. J Thromb Haemost 2003; 1: 2087-96.
25. Valls Serón M, Haiko J, De Groot PG, Korhonen TK, Meijers JCM. Thrombin-activatable fibrinolysis inhibitor is degraded by Salmonella enterica and Yersinia pestis. J Thromb Haemost 2010; 8: 2232-40.
26. Kremer Hovinga JA, Franco RF, Zago MA, Ten Cate H, Westendorp RGJ, Reitsma PH. A functional single nucleotide polymorphism in the thrombin-activatable fibrinolysis inhibitor (TAFI) gene associates with outcome of meningococcal disease. J Thromb Haemost 2004; 2: 54-7.
27. Schneider M, Boffa M, Stewart R, Rahman M, Koschinsky M, Nesheim M. Two naturally occurring variants of TAFI (Thr-325 and Ile-325) differ substantially with respect to thermal stability and antifibrinolytic activity of the enzyme. J Biol Chem 2002; 277: 1021-30.
28. Song JJ, Hwang I, Cho KH, Garcia MA, Kim AJ, Wang TH, Lindstrom TM, Lee AT, Nishimura T, Zhao L, Morser J, Nesheim M, Goodman SB, Lee DM, Bridges SL; Consortium for the Longitudinal Evaluation of African Americans with Early Rheumatoid Arthritis CLEAR Registry, Gregersen PK, Leung LL, Robinson WH. Plasma carboxypeptidase B downregulates inflammatory responses in autoimmune arthritis. J Clin Invest 2011; 121: 3517-27.
29. Frère C, Morange PE, Saut N, Tregouet DA, Grosley M, Beltran J, Juhan-Vague I, Alessi M-C. Quantification of thrombin activatable fibrinolysis inhibitor (TAFI) gene polymorphism effects on plasma levels of TAFI measured with assays insensitive to isoform-dependent artefact. Thromb Haemost 2005; 94: 373-9.
30. Henry M, Aubert H, Morange PE, Nanni I, Alessi MC, Tiret L, Juhan-Vague I. Identification of polymorphisms in the promoter and the 3' region of the TAFI gene: evidence that plasma TAFI antigen levels are strongly genetically controlled. Blood 2001; 97: 2053-8.
31. Heylen E, Miljic P, Willemse J, Djordjevic V, Radojkovic D, Colovic M, Elezovic I, Hendriks D. Procarboxypeptidase U (TAFI) contributes to the risk of thrombosis in patients with hereditary thrombophilia. Thromb Res 2009; 124: 427-32.
32. de Bruijne ELE, Darwish Murad S, de Maat MPM, Tanck MWT, Haagsma EB, van Hoek B, Rosendaal FR, Janssen HLA, Leebeek FWG; Liver and Thrombosis Study Group. Genetic variation in thrombin-activatable fibrinolysis inhibitor (TAFI) is associated with the risk of splanchnic vein thrombosis. Thromb Haemost 2007; 97: 181-5.
33. Tàssies D, Roqué M, Monteagudo J, Martorell T, Sionis A, Arzamendi D, Heras M, Reverter J-C. Thrombin-activatable fibrinolysis inhibitor genetic polymorphisms as markers of the type of acute coronary syndrome. Thromb Res 2009; 124: 614-18.
34. de Bruijne ELE, Gils A, Guimarães AHC, Dippel DWJ, Deckers JW, van den Meiracker AH, Poldermans D, Rijken DC, Declerck PJ, de Maat MPM, Leebeek FWG. The role of thrombin activatable fibrinolysis inhibitor in arterial thrombosis at a young age: the ATTAC study. J Thromb Haemost 2009; 7: 919-27.
35. Silander K, Alanne M, Kristiansson K, Saarela O, Ripatti S, Auro K, Karvanen J, Kulathinal S, Niemelä M, Ellonen P, Vartiainen E, Jousilahti P, Saarela J, Kuulasmaa K, Evans A, Perola M, Salomaa V, Peltonen L. Gender differences in genetic risk profiles for cardiovascular disease. PLoS ONE 2008; 3: e3615.
36. Morser J, Gabazza EC, Myles T, Leung LLK. What has been learnt from the thrombin-activatable fibrinolysis inhibitor-deficient mouse? J Thromb Haemost 2010; 8: 868-76.